What You Must Know Before Giving Blood

Thank you for coming in today!

This information sheet explains how YOU can help us make the donation process safe for yourself and patients who might receive your blood. PLEASE READ THIS INFORMATION BEFORE YOU DONATE! You will be asked to sign a statement that says you understand and have read this information today. If you have any questions now or anytime during the screening process, please ask blood center staff.

Accuracy And Honesty Are Essential

Your complete honesty in answering all questions is very important for the safety of patients who receive your blood. We will ask you for identification each time you try to donate. Please register using the same identifying information each time you donate (name, date of birth, etc.). All information you provide is confidential. Although your interview will be private, it may require more than one American Red Cross employee to participate in or be present at your health history and blood donation.

What happens when you give blood

To determine if you are eligible to donate we will:

- · ask questions about your health, travel, and medicines
- ask questions to see if you might be at risk for hepatitis, HIV, or AIDS
- take your blood pressure, temperature, and pulse, and
- take a small blood sample to make sure you are not anemic.

If you are able to donate we will:

- cleanse your arm with an antiseptic. (If you are allergic to Iodine, please tell us!),
 and
- use a new, sterile, disposable needle to collect your blood.

While you are donating: (the donation usually takes about 10 minutes)

• you may feel a brief "sting" from the needle at the beginning.

After donating we will give you

- · a form with post-donation instructions, and
- a number to call if you have any problems or decide after you leave that your blood may not be safe to give to another person.

What to expect after donating

Although most people feel fine before and after donating blood, a small number of people may have a(n)

- lightheaded or dizzy feeling
- upset stomach
- black and blue mark, redness, or pain where the needle was, and
- · very rarely, loss of consciousness, or nerve or artery damage.

We will give you a number to call to report any problems or concerns you may have following your donation.

Why we ask questions about sexual contact

Sexual contact may cause contagious diseases like HIV to get into the bloodstream and be spread through transfusions to someone else.

Definition of "sexual contact":

The words "have sexual contact with" and "sex" are used in some of the questions we will ask you, and apply to any of the following activities, whether or not a condom or other protection was used:

- vaginal sex (contact between penis and vagina)
- oral sex (mouth or tongue on someone's vagina, penis, or anus), and
- anal sex (contact between penis and anus).

Continued on back

What You Must Know Before Giving Blood, Continued

Persons who should not donate

You should not give blood if you

- · had hepatitis on or after the age of 11
- · had malaria in the past 3 years
- met any of the conditions listed in the CJD Information Sheet
- were held in a correctional facility (including jail, lock up, prison, or juvenile detention center) for more than 72 straight hours in the last 12 months.
- have had sexual contact in the past 12 months with anyone who is sick with hepatitis or AIDS
- · had or were treated for syphilis or gonorrhea or tested positive for syphilis in the last 12 months
- · were raped in the last 12 months
- have AIDS or have ever had a positive HIV test

AIDS is caused by HIV. HIV is spread mainly through sexual contact with an infected person, or by sharing needles or syringes used for injecting drugs.

· done something that puts you at risk for becoming infected with HIV

You are at risk for getting infected if you

- · have ever used needles to take drugs, steroids, or anything not prescribed by your doctor
- are a male who has had sexual contact with another male, even once, since 1977
- · have ever taken money, drugs, or other payment for sex since 1977
- have had sexual contact in the past 12 months with anyone described above
- received clotting factor concentrates for a bleeding disorder such as hemophilia
- were born in, or lived in, Cameroon, Central African Republic, Chad, Congo, Equatorial Guinea, Gabon, Niger, or Nigeria, since 1977.
- · since 1977, received a blood transfusion or medical treatment with a blood product in any of these countries, or
- had sex with anyone who, since 1977, was born in or lived in any of these countries.
- have any of the following conditions that can be signs or symptoms of HIV/AIDS
- unexplained weight loss (10 pounds or more in less than 2 months)
- · night sweats
- blue or purple spots in your mouth or skin
- · white spots or unusual sores in your mouth
- · lumps in your neck, armpits, or groin, lasting longer than one month
- · diarrhea that won't go away
- · cough that won't go away and shortness of breath, or
- · fever higher than 100.5 F lasting more than 10 days.

Ineligible donors

We maintain a confidential list of people who may be at risk for spreading transfusion-transmitted diseases. By continuing this process, you consent to be entered in this confidential list of deferred donors if you are at risk for spreading such diseases. When required, we report donor information, including test results, to health departments, military medical commands, and regulatory agencies. Donation information may also be used confidentially for medical studies.

If you decide <u>not</u> to give blood

If you decide that you should <u>not</u> give blood, you may leave now.

Testing your blood

Your blood will be tested for hepatitis, HIV (the virus that causes AIDS), syphilis, and other factors. (There are unusual circumstances in which these tests cannot be performed.) You will be notified about test results that may disqualify you from donating blood in the future or that may show you are unhealthy. Your blood will not be used if it could make someone sick. (A sample of your blood or a portion of your donation might be used now or in the future for additional tests or other medical studies. Please tell us if you object.)

Though the tests we use are very good, they are not perfect. HIV antibodies may take weeks to develop after infection with the virus. If you were infected recently, you might have a negative test result, yet be able to infect someone. That is why you must <u>not</u> give blood if you are at risk of getting AIDS or other infectious diseases. If you think you may be at risk for HIV/AIDS or want an HIV/AIDS test, please ask for information about other testing facilities. Please do not donate to get tested for HIV, hepatitis, or any other infections!

American Red Cross Blood Services

- Washington, DC 20006

Travel to or birth in other countries

Blood donor tests may not be available for some contagious diseases that are found only in certain countries.

If you were born in, have lived in, or visited certain countries, you may not be eligible to donate.

American Red Cross Biomedical Services Doc No ARC F6628CJD Version 05/08 Form: CJD Information Sheet					

What this form is about

This form explains Creutzfeldt-Jakob disease to the donor.

Who should use this form

This form applies to collections staff.

Revision History

Revision Number	Summary of Revisions				
07/04	Developed and released prior to revision history requirement				
05/08	 Removed watermark so sheet can be printed from eDOCs or eBinder Revised American Red Cross Logo Placed into System 3 Document template 				

CJD Information Sheet



Please do not donate if you-

- Since January 1, 1980 through December 31, 1996—
 - -Spent a total time that adds up to 3 months or more in any country(ies) in the United Kingdom (UK).
 - -The UK includes any of the countries listed in Table 1 below.
- Were a member of the U.S. military, a civilian military employee, or a dependent of a member of the U.S. military
 that spent a total time of 6 months on or associated with a military base in any of the following areas during the
 specified time frames—
 - -From 1980 through 1990 Belgium, the Netherlands (Holland), or Germany
 - -From 1980 through 1996 Spain, Portugal, Turkey, Italy, or Greece
- Since January 1, 1980 to present—
 - -Spent a total time that adds up to 5 years or more in Europe (includes time spent in the UK from
 - -1980 through 1996 and time associated with the military bases in Europe as outlined above).
 - -The European countries that are affected are listed below in Table 1 and Table 2.
 - -Received a blood transfusion in any country(ies) listed in Table 1 below.
 - -Received an injection of bovine (beef) insulin made in any of the countries listed below.
- Ever received—
 - -A dura mater (or brain covering) transplant during head or brain surgery.
 - -Human pituitary growth hormone (brain extract).
- Any blood relative has had Creutzfeldt-Jakob disease. A blood relative is your mother/father, grandparent, sibling, aunt/uncle, or children.
- Have been told that your family is at risk for Creutzfeldt-Jakob disease.

If any of these apply to you, your donation cannot be accepted. If you have any questions, please ask us. We sincerely appreciate your support.

	Table 1
Channel Islands England	 United Kingsom Falkland Islands
	Table 2
	SEUROPEAR PROPERTY OF THE PROP
 Albania Austria Belgium Bosnia/Herzegovina Bulgaria Croatia Czech Republic Denmark Finland France Germany Greece 	 Hungary Ireland (Republic of) Italy Kosovo (Federal Republic of Yugoslavia) Liechtenstein Luxembourg Macedonia Montenegro (Federal Republic of Yugoslavia) Spain Sweden Montenegro (Federal Republic of Yugoslavia) Turkey Netherlands (Holland) Portugal Romania Serbia (Federal Republic of Yugoslavia) Slovak Republic (Slovakia) Slovenia Spain Sweden Switzerland Turkey Yugoslavia (Federal Republic includes Kosovo, Montenegro, and Serbia)

###

American Red Cross Biomedical Services Form: CJD Information Sheet Page 1 of 1 ARC F6628CJD 05/08 American Red Cross Biomedical Services

Job Aid: Medication Deferral List

Doc No Version
14.4.ja021 1.1

Approved by

Quality Assurance

Approval date 05.04.06

Please tell us if you are now taking	or if you have E	VER taken	any of these
medications:			

Proscar® (finasteride) – usually given for prostate gland enlargement
Avodart® (dutasteride) – usually given for prostate enlargement
Propecia® (finasteride) – usually given for baldness
Accutane®, Amnesteem®, Claravis®, or Sotret®, (isotretinoín) – usually given for severe acne
Soriatane® (acitretin) – usually given for severe psoriasis
Tegison® (etretinate) - usually given for severe psoriasis
Growth Hormone from Human Pituitary Glands – used only until 1985, usually for children with delayed or impaired growth
Insulin from Cows (Bovine, or Beef, Insulin) – used to treat diabetes
Hepatitis B Immune Globulin – given following an exposure to hepatitis B
Note: This is different from the hepatitis B vaccine which is a series of 3 injections given over a 6 month period to prevent future infection from exposures to hepatitis B.
Unlicensed Vaccine – usually associated with a research protocol

Please tell us if you are now taking or if you have taken any of these medications in the last 7 days:

- Clopidogrel
- Coumadin (warfarin)
- Heparin
- Plavix
- Ticlid
- Ticlopidine

IF YOU WOULD LIKE TO KNOW WHY THESE MEDICINES AFFECT YOU AS A BLOOD DONOR, PLEASE KEEP READING:

- If you have taken or are taking Proscar, Avodart, Propecia, Accutane, Amnesteem, Claravis, Sotret, Soriatane, or Tegison, these medications can cause birth defects. Your donated blood could contain high enough levels to damage the unborn baby if transfused to a pregnant woman. Once the medication has been cleared from your blood, you may donate again. Following the last dose, the deferral period is one month for Proscar, Propecia, Accutane, Amnesteem, Claravis or Sotret, six months for Avodart and three years for Soriatane. Tegison is a permanent deferral.
- Growth hormone from human pituitary glands was prescribed until 1985 for children with delayed or impaired growth. The hormone was obtained from human pituitary glands, which are found in the brain. Some people who took this hormone developed a rare nervous system condition called Creutzfeldt-Jakob Disease (CJD, for short). The deferral is permanent. CJD has not been associated with growth hormone preparations available since 1985.
- CJD has been reported in extremely rare cases in Australian women who took gonadotropin from human pituitary glands for treatment for infertility. Gonadotropin from human pituitary glands was manufactured and distributed outside the United States and was never marketed in the United States to treat infertility. Human chorionic gonadotropin which is used for fertility treatments in the United States is not derived from human pituitary glands and is not a cause for deferral.
- Insulin from cows (bovine, or beef, insulin) is an injected material used to treat diabetes. If this insulin was imported into the US from countries in which "Mad Cow Disease" has been found, it could contain material from infected cattle. There is concern that "Mad Cow Disease" is transmitted by transfusion. The deferral is indefinite.
- Hepatitis B Immune Globulin (HBIG) is an injected material used to prevent infection following an
 exposure to hepatitis B. HBIG does not prevent hepatitis B infection in every case, therefore persons
 who have received HBIG must wait 12 months to donate blood to be sure they were not infected since
 hepatitis B can be transmitted through transfusion to a patient.
- Unlicensed Vaccine is usually associated with a research protocol and the effect on blood transmission is unknown. The deferral is for one year.
- If you have taken Ciopidogrel, Plavix Ticlid, or Ticlopidine in the last 7 days, these medications affect the portion of your blood called platelets. If you are donating platelets, your donated blood could contain high enough levels of the medications that it could affect the quality of the platelets that you give. Once the medication has been cleared from your blood, you may donate platelets again. Following the last dose, the deferral period is 7 days.
- If you have taken Coumadin (Warfarin) or Heparin in the last 7 days, these medications can affect the blood's ability to clot, which might cause excessive bruising or bleeding when you donate. Therefore, we ask that you be off of these drugs for 7 days prior to giving blood. Following the last dose, the deferral period is 7 days.

###

American Red Cross Biomedical Services Job Aid: Medication Deferral List May 2006

Page 2 of 2 14.4.ja021 v-1.1 American Red Cross Biomedical Services Washington, DC 20006

Controlled Documents Approval

SECTION 1: Document Package Information

Transmittal Sheet Title: Revised health History Tables and Related Douments Version: 1.0

Number: 2522

Document Title:

Time Period: May 2006

List Documents Here:	14.4.ja041, v-1.1	14.4.tbl010, v-1.4
14.3.019, v-1.3	14.4.ja049, v-1.2	14.4.tbl011, v-1.2
14.3.070, v-1.2	14.4.tbl001, v-1.3	14.4.tbl012, v-1.2
14.3.092, v-1.2	14.4.tbl002, v-1.3	14.4.tbl016, v-1.3
14.3.094, v-1.2	14.4.tbl003, v-1.4	14.4.tbl021, v-1.2
14.4.ja021, v-1.1	14.4.tbl004, v-1.4	14.4.tbl023, v-1.3
14.4.ja028, v-1.2	14.4.tbl005, v-1.2	14.4.tbl024, v-1.3
14.4.ja029, v-1.4	14.4.tbl006, v-1.3	14.4.tbl025, v-1.2
14.4.ja031, v-1.3	14.4.tbl008, v-1.2	14.4.tbl026, v-1.2
14.4.ja032, v-1.1	14.4.tbl009, v-1.3	
List Documents Here		
(continued):		
14.4.tbl027, v-1.2	14.4.tbl039, v-1.3	
14.4.tbl028, v-1.2	14.4.tbl044, v-1.3	
14.4.tbl029, v-1.4	14.4.tbl045, v-13.	
14.4.tbl030, v-1.2	14.4.tbl046, v-1.3	
14.4.tbl031, v-1.3	14.4.tbl047, v-1.3	
14.4.tbl033, v-1.2	14.4.tbl048, v-1.3	
14.4.tbl034, v-1.4	14.4.tbl201, v-1.1	
14.4.tbl035, v-1.2	14.4.tbl202, v-1.1	
14.4.tbl036, v-1.2	14.4.tbl208, v-1.1	

American Red Cross Biomedical Services Washington, DC 20006

Controlled Documents Approval

SECTION 2: Approvals

Your approval signifies that you have reviewed the documents according to the requirements for your functional area.

Signatory Name	Role	Signature	Date
Please print or type name here Pat Demaris	Check role Process Owner CEO/ Division VP None	Pat Dena	ns 05/05/06
Anne Eder	Medical Office None	Am &	Lu oslos lo b
	Executive QA System QA SiT-QRM		
		The Quality of	15.05.06



平成15年度 厚生労働科学研究費補助金 (医薬品等医療技術リスク評価研究事業) 分担研究報告書

4. 採血により献血者に起こる副作用・合併症の解析

一平成14年の全国データから一

分担研究者


佐竹 正博 (東京都赤十字血液センター) 中村 榮一 (東京都赤十字血液センター)

日本赤十字社では、献血時の採血によって献血者に起こる副作用や合併症のデータを集積しているが、ここでは全国の血液センターから集められた平成14年のデータをもとに解析を試みた。


まず、すべての採血種における全献血者の副作用の頻度を表に示した。

	YVR 軽症	VYR 重症	神経損傷	皮下出血	クエン酸中毒	その他	合計
%	0. 73	0.026	0.011	0. 23	0.011	0.039	1.04


全献血者の約1%に何らかの副作用が起こっており、その73%は VVR(vasovagal reaction、血管迷走神経反応)である。献血者に長期にわたる愁訴・運動障害などを起こす可能性のある神経損傷が1万人に1.1人の確率で起こることは重大である。副作用の割合を示したのが図1である。 VVR に次いで、皮下出血が22%を占めている。



これを男女別にみたのが次の図2である。




男女別でとくにパターンの大きな変化はないが、すべての副作用において女性のほうがその頻度が高い。しかしながら、これを採血種別にみていくと男女間でかなり大きな差があることがわかる。図3は比較的軽症のWRの発生頻度を採血種別にみたものである。



200mL 採血では男女ほぼ同じ頻度で VVR が起こっているが、400mL になると女性のほうが有意に多くなる。これは、女性のほうが一般に循環血液量が少なく、血管内の volume loss による症状が現れやすく、それが VVR に加算されて頻度が高くなったものと思われる。PC や PPP の成分採血になると、男性ではむしろ VVR が少なくなっているのに対し、女性ではさらに頻度が高くなっている。女性で多くなるのは、前述のように血漿採取量の増加の影響が出ているものと思われるが、男性でかえって少なくなる理由は不明である。男性の場合、血漿採取量が循環血液量に影響を及ぼさない範囲では、専用椅子に1時間近くゆっくり座って採血を受ける成分採血の方が心理

的に余裕があり、VVR が起こりにくいこともあるのではないかと想像される。

重症の WR では図4にように 200ml 採血ではむしろ男性の方が多い。成分採血では女性は男性の5倍ほど重大



な転帰をとりやすい。男女とも 200ml 採血では循環血液量に影響が出ることはほとんど考えられないので、この 採血において男女の VVR の頻度がほぼ同じであることは、純粋に神経学的な機序のみで起こる VVR の頻度に性差 はあまりないことを示すものといえる。図5 は軽症と重症を合わせた全 VVR の頻度である。






図6は神経損傷の頻度である。ここでは予想されるように採血種別による頻度の差はほとんどない。これはいっぽうでこのデータ収集が大きな片寄りのないものである事を示すものと思う。女性のほうがどの採血種別でも男性より頻度が高い。女性はより痛みに敏感であることが影響していると思われる。これは RSD(reflex



sympathetic dystrophy)などが女性に多いといわれる事などからも推察される。

図7は皮下出血の頻度である。特徴的なのは、200ml、400ml 採血ではどちらも同程度に頻度が低いのに対し、成分採血では約6倍ぐらい高いことである。これは、穿刺針が長時間静脈内に留置されている間に血管壁を傷つ



ける可能性が高いためであると考えられるが、さらに、長時間異物が挿入されていることにより、創傷の治癒機 転が少なからず阻害される事もあるのではないかと考えられる。どの採血種でも女性は男性のちょうど2倍の報 告がある。女性の方が美容上より気にしやすいこともあるだろうが、破綻血管からの止血について女性が本質的 に弱点を持っている可能性はないだろうか。

図8はクエン酸中毒の頻度で、母集団は成分採血者のみとした。血漿採血(PPP)よりも血小板採血(PC)の方が遥かにクエン酸中毒を起こしやすい。これは採取血小板の凝集を防ぐために PC 採取の場合は ACD 輸注比を高く設定するためと、PC 採取の方が時間が長くかかるためと思われる。また、女性の方が圧倒的に頻度が高いのは、体格が小さいために循環血液量が少なく、クエン酸の血中濃度が高くなりやすいためと思われる。




図9はその他の副作用である。






図10は、すべての採血副作用・合併症の合計の頻度を採血種別、男女別に合計したものである。おもしろいことに、男性ではすべての採血種でほぼ同じ合併症頻度を示す。これに対し女性では、200元、400元、PPP、PC の順に直線的に頻度が高まっていく。これに最も寄与しているのが VVR で、以下皮下出血、クエン酸中毒と続く。女性の PC 採血者において 2.5%もの献血者に副作用が出ている事実は注目されなければならない。血小板採取で起こる副作用をまとめると図11のようになり、女性においては VVR、次に皮下出血の順となる。成分採血後の止血法については改善の余地がある。





まとめ

全献血者の約1%に何らかの副作用・合併症が起こる。その73%は VVR であり、皮下出血が22%である。女性は男性の1.87倍合併症が起こりやすい。採血種別では、PC 採血において最も頻度が高く、PPP、400mL と続く。これは女性にのみ認められる現象で、男性ではどの採血種別でも同じ頻度である。女性でこの頻度を高くしているのが VVR、次いで皮下出血である。

男性において、採血の環境・状況が異なるどの採血種でも頻度が同じであり、また 200ml 採血では男女の差はまったくないことは、この頻度が日本で不可避的に起こる採血合併症の頻度ではないかということを示唆する。いっぽう、女性での頻度の増加分は採血状況の何らかの改善によって防ぎうるものではないかということも示唆す